Humana Inc. (NYSE:HUM) to Post Q1 2024 Earnings of $6.07 Per Share, Zacks Research Forecasts

Humana Inc. (NYSE:HUMFree Report) – Zacks Research reduced their Q1 2024 earnings per share estimates for Humana in a research note issued on Thursday, February 8th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will post earnings per share of $6.07 for the quarter, down from their prior forecast of $10.48. The consensus estimate for Humana’s current full-year earnings is $16.03 per share. Zacks Research also issued estimates for Humana’s Q2 2024 earnings at $5.58 EPS, Q3 2024 earnings at $4.23 EPS, Q4 2024 earnings at $0.14 EPS, FY2024 earnings at $16.02 EPS, Q1 2025 earnings at $6.16 EPS, Q2 2025 earnings at $6.20 EPS, Q3 2025 earnings at $5.46 EPS, Q4 2025 earnings at $4.50 EPS and FY2025 earnings at $22.32 EPS.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. During the same quarter in the prior year, the firm earned $1.62 earnings per share. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year.

HUM has been the topic of several other research reports. The Goldman Sachs Group cut their target price on Humana from $515.00 to $450.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. JPMorgan Chase & Co. cut their price objective on Humana from $593.00 to $575.00 and set a “neutral” rating on the stock in a research report on Friday, November 17th. Cantor Fitzgerald lowered Humana from an “overweight” rating to a “neutral” rating and cut their price target for the company from $597.00 to $391.00 in a research note on Friday, January 26th. Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $550.00 price target on the stock in a research note on Tuesday, December 12th. Finally, Wells Fargo & Company cut their price target on Humana from $465.00 to $413.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 30th. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, Humana currently has an average rating of “Moderate Buy” and an average price target of $506.72.

Check Out Our Latest Report on Humana

Humana Stock Performance

NYSE:HUM opened at $369.14 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.37. Humana has a 1 year low of $342.69 and a 1 year high of $541.21. The stock’s 50 day simple moving average is $432.41 and its two-hundred day simple moving average is $470.98. The company has a market cap of $45.44 billion, a price-to-earnings ratio of 18.62, a PEG ratio of 2.17 and a beta of 0.46.

Hedge Funds Weigh In On Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rakuten Securities Inc. purchased a new stake in shares of Humana in the 4th quarter valued at $25,000. Sunbelt Securities Inc. purchased a new position in shares of Humana during the 1st quarter worth approximately $28,000. Gradient Investments LLC raised its stake in shares of Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after buying an additional 40 shares in the last quarter. Cetera Trust Company N.A purchased a new position in shares of Humana during the 4th quarter worth approximately $28,000. Finally, WFA of San Diego LLC purchased a new position in shares of Humana during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 91.86% of the company’s stock.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.